Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Lymphoma 221Lymphoma, Non-Hodgkin 194Leukemia, Lymphocytic, Chronic, B-Cell 175Lymphoma, Large B-Cell, Diffuse 170Lymphoma, Follicular 164Lymphoma, B-Cell 108Lymphoma, Mantle-Cell 102Hodgkin Disease 99Recurrence 94Leukemia, Myeloid, Acute 94Multiple Myeloma 89Burkitt Lymphoma 86Leukemia 76Neoplasms 66Hematologic Neoplasms 58Lymphoma, B-Cell, Marginal Zone 56Myelodysplastic Syndromes 52Waldenstrom Macroglobulinemia 42Lymphoma, T-Cell 42Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma, T-Cell, Peripheral 35Lymphoma, T-Cell, Cutaneous 31Leukemia, Biphenotypic, Acute 28Leukemia, Myelogenous, Chronic, BCR-ABL Positive 27Leukemia, B-Cell 27Mycosis Fungoides 25Lymphoma, Large-Cell, Anaplastic 25Sarcoma 24Lymphoproliferative Disorders 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pneumonia × Lymphoid × 90 days × Clear all
NCT05962606 2026-03-18

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

Aptarion Biotech AG

Phase 2 Completed
150 enrolled
Lymphoid

Community-Acquired Pneumonia, Lymphoma, Follicular, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡